Gabor Maté and experts like Dennis McKenna and Rick Doblin discuss the therapeutic potential of psychedelics such as LSD, Psilocybin, and Ayahuasca.
Synopsis
Gabor Maté and experts like Dennis McKenna and Rick Doblin discuss the therapeutic potential of psychedelics such as LSD, Psilocybin, and Ayahuasca.
Go deeperPeople
View all →
Synopsis
Gabor Maté and other experts discuss the therapeutic potential of psychedelic substances in Neurons to Nirvana. The film features interviews with notable figures such as Dennis McKenna and Rick Doblin, who address the medicinal benefits of LSD, Psilocybin, MDMA, and Ayahuasca. It also critiques the societal and political barriers that have limited research into these drugs. Released in 2013, the documentary runs for 69 minutes and includes animated sequences from Ben Ridgway's film Continuum Infinitum.
Deep Dive
Why Watch
- Meet experts like Gabor Maté and Dennis McKenna.
- Find out about the crowdfunding success of over $35,000.
- See animated scenes from Continuum Infinitum.
Did You Know
- The film raised over $35,000 through a Kickstarter campaign.
- The director's cut runs for 108 minutes, while the shorter version is 69 minutes.
- The film features interviews with 20 experts in the field of psychedelics.
- The director's cut premiered at the Vancouver Film Festival in 2013.
Perfect For
Frequently Asked Questions
Who directed the documentary Neurons to Nirvana?
Neurons to Nirvana was directed by Canadian filmmaker Oliver Hockenhull.
What is the runtime of the director's cut of Neurons to Nirvana?
The director's cut of Neurons to Nirvana runs for 108 minutes.
How much money was raised through the Kickstarter campaign for Neurons to Nirvana?
The Kickstarter campaign for Neurons to Nirvana raised more than $35,000.
Awards & Festivals
What are people saying?
Play More Like This
Browse more like this
Browse more by Oliver Hockenhull
View all films →
Related Films
Is this your film?
If you made this film or hold the rights to it, we'd like to talk. We can license it and pay you a share of what it earns.
Comments